HRP20140686T1 - Poboljšani postupak - Google Patents

Poboljšani postupak Download PDF

Info

Publication number
HRP20140686T1
HRP20140686T1 HRP20140686AT HRP20140686T HRP20140686T1 HR P20140686 T1 HRP20140686 T1 HR P20140686T1 HR P20140686A T HRP20140686A T HR P20140686AT HR P20140686 T HRP20140686 T HR P20140686T HR P20140686 T1 HRP20140686 T1 HR P20140686T1
Authority
HR
Croatia
Prior art keywords
process according
alcohol
solvent system
methanol
lenalidomide
Prior art date
Application number
HRP20140686AT
Other languages
English (en)
Croatian (hr)
Inventor
Vinayak Gore
Vinay Kumar Shukla
Sheryas Bhandari
Suresh Hasbe
Original Assignee
Generics
UK] Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics, UK] Limited filed Critical Generics
Publication of HRP20140686T1 publication Critical patent/HRP20140686T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Optical Communication System (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
  • Glass Compositions (AREA)
HRP20140686AT 2009-03-02 2010-03-01 Poboljšani postupak HRP20140686T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN383KO2009 2009-03-02
IN463KO2009 2009-03-16
PCT/GB2010/050352 WO2010100476A2 (en) 2009-03-02 2010-03-01 Improved process

Publications (1)

Publication Number Publication Date
HRP20140686T1 true HRP20140686T1 (hr) 2014-09-26

Family

ID=54290149

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140686AT HRP20140686T1 (hr) 2009-03-02 2010-03-01 Poboljšani postupak

Country Status (16)

Country Link
US (1) US8946265B2 (https=)
EP (1) EP2403845B1 (https=)
JP (1) JP5727944B2 (https=)
CN (1) CN102414196A (https=)
AU (1) AU2010220204B2 (https=)
CA (1) CA2753241C (https=)
CY (1) CY1115376T1 (https=)
DK (1) DK2403845T3 (https=)
ES (1) ES2487215T3 (https=)
HR (1) HRP20140686T1 (https=)
NZ (1) NZ595492A (https=)
PL (1) PL2403845T3 (https=)
PT (1) PT2403845E (https=)
SI (1) SI2403845T1 (https=)
SM (1) SMT201400100B (https=)
WO (1) WO2010100476A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide
WO2011111053A1 (en) * 2010-03-08 2011-09-15 Natco Pharma Limited Anhydrous lenalidomide form-i
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
WO2013005229A1 (en) * 2011-07-05 2013-01-10 Hetero Research Foundation Process for lenalidomide
US9540341B2 (en) 2011-07-19 2017-01-10 Amplio Pharma, Llc Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN102838586A (zh) * 2012-09-20 2012-12-26 重庆泰濠制药有限公司 一种制备来那度胺的方法
WO2014164285A2 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
RU2015134423A (ru) 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
MX382776B (es) 2013-03-13 2025-03-13 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
US9808450B2 (en) 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103601717A (zh) * 2013-10-09 2014-02-26 湖南华腾制药有限公司 一种来那度胺的新型制备方法
LV14985B (lv) 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process
WO2014155371A2 (en) * 2014-04-26 2014-10-02 Shilpa Medicare Limited Crystalline lenalidomide process
WO2016024286A2 (en) * 2014-08-11 2016-02-18 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide
EP3183244B1 (en) * 2014-08-19 2019-04-10 Synthon BV Process for making crystalline form a of lenalidomide
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
WO2017109041A1 (en) * 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
EP3687987A4 (en) * 2017-09-27 2021-03-24 Biocon Limited CRYSTALLINE FORMS OF LENALIDOMIDE
US11452722B2 (en) 2018-01-11 2022-09-27 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN111196800B (zh) * 2018-11-19 2022-10-11 欣凯医药化工中间体(上海)有限公司 一种制备来那度胺的方法
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
WO2022144924A1 (en) * 2021-01-04 2022-07-07 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
BRPI0514865A (pt) * 2004-09-03 2008-06-24 Celgene Corp processo para preparar um composto
US8304250B2 (en) 2007-04-16 2012-11-06 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating N-glycans
CA2709262A1 (en) 2007-12-14 2009-06-25 Generics [Uk] Limited New hplc method
CA2717326C (en) 2008-03-11 2018-10-23 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
WO2010061209A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited A crystalline form of lenalidomide and a process for its preparation
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide

Also Published As

Publication number Publication date
CA2753241C (en) 2015-06-16
AU2010220204B2 (en) 2015-10-08
SI2403845T1 (sl) 2014-09-30
DK2403845T3 (da) 2014-08-04
PL2403845T3 (pl) 2014-09-30
US8946265B2 (en) 2015-02-03
CY1115376T1 (el) 2017-01-04
ES2487215T3 (es) 2014-08-20
WO2010100476A2 (en) 2010-09-10
PT2403845E (pt) 2014-08-04
SMT201400100B (it) 2014-11-10
NZ595492A (en) 2013-07-26
JP5727944B2 (ja) 2015-06-03
US20120071509A1 (en) 2012-03-22
JP2012519207A (ja) 2012-08-23
EP2403845A2 (en) 2012-01-11
CN102414196A (zh) 2012-04-11
WO2010100476A3 (en) 2011-06-16
AU2010220204A1 (en) 2011-10-20
EP2403845B1 (en) 2014-04-30
CA2753241A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
HRP20140686T1 (hr) Poboljšani postupak
HRP20160885T1 (hr) Postupak za pripremu oksikodon hidroklorida koji sadrži manje od 25ppm 14-hidroksikodeinona
RS59402B1 (sr) Postupak za pripremu beta 3 agonista i međuproizvoda
NZ625798A (en) Processes for the manufacture of a pharmaceutically active agent
DE602005023459D1 (de) Verfahren zur herstellung und reinigung von 2-hydrocarbyl-3,3-bis(4-hydroxyaryl-phthalimidin-monomeren
NO20093037L (no) Fremgangsmate for fremstilling av maursyre
US8853402B2 (en) Process for reducing the 6-keto group of a morphinan alkaloid to the 6-hydroxy group by hydrogenation
MX384709B (es) Proceso de hidrogenación catalítico para preparar pirazoles.
CN102285891A (zh) 一种由芳香硝基化合物催化加氢制备芳胺的方法
NO20050534L (no) Metode og utstyr for fremstilling av formiater og deres anvendelse
RS60184B1 (sr) Postupak za dobijanje antagonista androgenog receptora i njihovih međuproizvoda
CN114644614B (zh) 一种左旋烟碱的制备方法
ATE544743T1 (de) Verfahren zur isolierung eines organischen amins
WO2009135598A8 (en) Process for preparing substituted biphenylanilides
CN102596908A (zh) 用于制备取代的吲唑和氮杂吲唑化合物的中间体的合成方法
DE602005016223D1 (de) Neues verfahren zur synthese substituierter alpha-aminoindanderivate
EA201291209A1 (ru) Способ получения феррохина конвергентным восстановительным аминированием
Pan et al. Organocatalytic asymmetric biomimetic transamination of α-keto acetals to chiral α-amino acetals
ATE534643T1 (de) Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers
MX2010014510A (es) Sintesis de aminas quirales.
Wen et al. Rhodium (III)-catalyzed internal oxidative coupling of N-hydroxyanilides with alkenes via C–H activation
Saito et al. Continuous-flow reductive N-methylation with highly active heterogeneous Pd catalysts and sequential-flow synthesis of N-monomethyl amines
HRP20150617T1 (hr) Asimetriäśni postupak redukcije
CN115583979B (zh) 一种8-(二苯基膦)喹啉铁配合物催化剂的制备方法及其应用
WO2011091677A1 (zh) 阿利吉仑中间体3-氨基-2,2-二甲基丙酰胺的制备方法